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Abstract
OBJECTIVES: There is currently a lack of clinical data on the novel
beta-coronavirus infection [caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)] and concomitant primary
lung cancer. Our goal was to report our experiences with 5
patients treated for lung cancer while infected with SARS-CoV-2.
METHODS: We retrospectively evaluated 5 adult patients infected
with SARS-CoV-2 who were admitted to our thoracic surgery unit
between 29 January 2020 and 4 March 2020 for surgical treatment
of a primary lung cancer. Clinical data and outcomes are
reported.
RESULTS: All patients were men with a mean age of 74.0 years
(range 67–80). Four of the 5 patients (80%) reported chronic
comorbidities. Surgery comprised minimally invasive lobectomy
(2 patients) and segmentectomy (1 patient), lobectomy with en
bloc chest wall resection (1 patient) and pneumonectomy (1 pa-
tient). Mean chest drain duration was 12.4 days (range 8–22);
mean hospital stay was 33.8 days (range 21–60). SARS-CoV-2-
related symptoms were fever (3 patients), persistent cough (3
patients), diarrhoea (2 patients) and syncope (2 patients); 1 patient
reported no symptoms. Morbidity related to surgery was 60%; 30-
day mortality was 40%. Two patients (1 with a right pneumonec-
tomy, 74 years old; 1 with a lobectomy with chest wall resection
and reconstruction, 70 years old), developed SARS-CoV-2-related
lung failure leading to death 60 and 32 days after surgery,
respectively.
CONCLUSIONS: Lung cancer surgery may represent a high-risk
factor for developing a severe case of coronavirus disease 2019,
particularly in patients with advanced stages of lung cancer.
Additional strategies are needed to reduce the risk of morbidity
and mortality from SARS-CoV-2 infection during treatment for
lung cancer.
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ABBREVIATIONS
COPD Chronic obstructive pulmonary disease
COVID-19 Coronavirus disease 2019
CT Computed tomography
GGO Ground-glass opacity
NSCLC Non-small-cell lung cancer
SARS-CoV-2 Severe acute respiratory syndrome
coronavirus 2
INTRODUCTION
Since December 2019, the world health care community has
faced a difficult challenge with the novel beta-coronavirus known
as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) [1, 2]. Because it is highly contagious, SARS-CoV-2 progressive-
ly spread from China to almost every country around the globe;
Italy was the second country to be hit by the epidemic. Tuscany,
in central Italy, has been massively involved after the regions of
northern Italy (Lombardy and Veneto) [3]. The intense involve-
ment of hospitals in the care of patients infected with SARS-CoV-
2 and the extensive use of the intensive care required by patients
with coronavirus disease 2019 (COVID-19) [2] limited elective
surgical activity, including oncological surgery. Furthermore, can-
cer patients are more susceptible to infection than individuals
without cancer because of their systemic immunosuppressive
state caused by the malignancy and the anticancer treatments
[4–6]. Therefore, these patients may be at increased risk of con-
tracting COVID-19 and have a poorer prognosis. In addition, a
significant delay in surgical treatment may jeopardize their long-
term survival and quality of life. There is also serious concern that
some oncological diagnostic and therapeutic procedures, includ-
ing bronchoscopy, double-lumen orotracheal intubation and
lung resections in patients with a prolonged air leak may expose
health care personnel to breath-borne viruses. Given these facts,
thoracic surgeons must choose which patients should be consid-
ered as needing urgent treatment or at least which ones for
whom treatment should not be postponed and which patients
with lung cancer are more at risk of dying if they have a lung re-
section while being infected with SARS-CoV-2. Our goal was to
report our experience with 5 patients surgically treated for a pri-
mary lung cancer while infected with SARS-CoV-2 at the begin-
ning of the epidemic in Tuscany.
MATERIALS AND METHODS
At the onset of the SARS-CoV-2 epidemic in Italy, oncological
surgical activity in the thoracic surgery unit was not interrupted.
A total of 79 patients were operated on during this period. For
this study, we retrospectively evaluated 5 adult patients infected
with SARS-CoV-2 who were admitted to our thoracic surgery
unit between 29 January 2020 and 4 March 2020 for surgical
treatment of a primary lung cancer. When a patient in the early
postoperative period of a video-assisted thoracic surgery seg-
mentectomy for a non-small-cell lung cancer (NSCLC) had an
unexplained persistent fever and dry cough, we performed a
nasopharyngeal coronavirus swab test. The test result was posi-
tive for SARS-CoV-2. We then tested the other 11 patients in our
unit for SARS-CoV-2; 4 of 11 patients who had undergone
surgery for lung cancer had positive test results. Of the 67
patients who had already been operated on and discharged,
none developed symptoms related to SARS-CoV-2 infection. We
performed nasopharyngeal coronavirus swab tests in 12 of these
patients because of a positive family history of exposure; the
results of all 12 tests were negative. Lymphopenia was defined as
a count <0.4 109/l. Chest drain management was standard:
continuous aspiration (20 cm H2O) for the first 24 h; tube re-
moval after 12 h with no air leak and liquid production <4 ml/kg/
24 h. Health care personnel who had been involved in patient
management were also tested for SARS-CoV-2. The study was
approved by the institutional SARS-CoV-2 scientific committee
(ID:09, 17 April 2020).
RESULTS
Demographic and clinical data are shown in Table 1; postopera-
tive computed tomography (CT) scans are exhibited in Fig. 1. All
patients were men with a mean age of 74.0 years (range 67–80).
Comorbidities were present in 80%; 3 (60%) patients were treated
with a minimally invasive approach. Mean chest drain duration
was 12.4 days (range 8–22); it was prolonged because of liquid
production in 3 cases and air leak in 2. The mean hospital stay
was 33.8 days (range 21–60). SARS-CoV-2-related symptoms
were present in 4 patients (80%); lymphopenia was observed in 2
(40%) patients and anaemia requiring transfusions (haemoglobin
<8 g/dl) was noted in 3 (60%) patients. postoperative morbidity
related to the thoracic surgical procedure was 60%. The 30-day
mortality was 40% (Table 1). Once the disease was diagnosed,
treatment against SARS-CoV-2 was started, including antiviral
medications, oxygenation, subcutaneous low-molecular-weight
heparin (4.000 units/24 h) and other supportive care when
needed (Table 1). For those patients who were discharged, low-
molecular-weight heparin was continued for 2 weeks at home. A
total of 150 health care workers who were identified as being at
high risk of infection were given the nasopharyngeal coronavirus
swab test: 3 (2%) of them had positive test results but none devel-
oped a severe case of COVID-19.
The following is a case by case description of the clinical
reports.
Case 1
Case 1 was a male patient, 67 years of age, who was admitted
for evaluation of an NSCLC of the lower lobe of the right lung
(cT1aN0M0). He had a medical history of rheumatoid arthritis
and of a squamous laryngeal tumour treated with surgery and
adjuvant chemotherapy 10 years before; he was also a former
smoker (40 pack/year, who stopped 2 years ago). Chest CT scans
showed an irregular solid nodule in the lower lobe (S7) with no
ground-glass opacities (GGOs) in the remaining lung. A trans-
bronchial guided biopsy revelled a primary squamous cell car-
cinoma of the lung. The patient appeared well, with no fever or
respiratory symptoms. On day 1 of hospitalization, he had a
thoracoscopic resection of segment 7 associated with hilar and
mediastinal lymphadenectomies, without incidence. On postop-
erative day 3, he had an intermittent fever (38.5C) with peaks
to 39.5C. We started empirical antibiotic therapy (piperacillin
and vancomycin). The results of a blood culture were negative.
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changes in the right lower lobe (parenchymal opacity) with no
distant GGO in the remaining lung areas. Blood and urinary cul-
tures revealed no bacterial infections. The white blood cell count
was 13.5 1012/l on postoperative day 2 and progressively
dropped to 4.6 1012/l on postoperative day 10; the lympho-
cyte count was lowered to 0.4 109/l and the differential to 5%.
The C-reactive protein level was always slightly high (about
300 ng/l) whereas the procalcitonin levels were normal. Based
on the persistence of the fever and on the development of dys-
pnoea, chest tightness, wheezing and dry cough, on postopera-
tive day 10 we performed another chest X-ray, which showed
bilateral infiltrates in the lower lobes. The pharyngeal swab test
for SARS-CoV-2 was performed. When the results of the test
were positive, that same day the patient was transferred to the
SARS-CoV-2 isolation ward for treatment as described. The
patient’s condition progressively improved; he was discharged
on postoperative day 21 with no symptoms, no fever and no
need for oxygen therapy.
Case 2
Case 2 was a 74-year-old male ex-smoker (30 pack/year), with a
history of chronic obstructive pulmonary disease (COPD). The
patient was admitted for elective surgery for lung cancer
(cT3N0M0). Three months before hospitalization, a CT scan
showed a central hilar positron emission tomography positive
lesion of the right lung. The results of invasive mediastinal stag-
ing were negative. A first surgical treatment comprising a right
sleeve upper lobectomy extended to segment S6 was compli-
cated by complete vein thromboses with parenchymal necrosis
and infection so that he underwent a completion pneumonec-
tomy on postoperative day 6. The subsequent period was char-
acterized by progressive severe anaemia with no demonstration
of any bleeding source that required transfusions on postopera-
tive day 10, fever (38.2C) and diarrhoea since postoperative day
8. Fever persisted despite broad-spectrum antibiotic therapy
(piperacillin and vancomycin), as did coughing; progressive lym-
phopenia with lowered lymphocyte count appeared. Because
the patient was exposed to case 1, a pharyngeal swab test for
SARS-CoV-2 was performed; positive results were obtained on
postoperative day 46. The patient was then transferred to the
SARS-CoV-2 isolation ward for specific treatment. He gradually
recovered until postoperative day 60, when he died of a pul-
monary embolism.
Case 3
Case 3 was an ex-smoker (40 pack/year), 70-year-old man with a
history of COPD and hypothyroidism. The patient was diagnosed
with a primary adenocarcinoma of the right upper lobe, involv-
ing the chest wall (2-3-4 ribs), cT3N0M0. After induction chemo-
therapy and radiotherapy (complicated by a urinary tract
infection with left hydronephrosis, which needed a nephros-
tomy), the patient underwent a standard lobectomy with en bloc
chest wall resection plus mediastinal lymph node radical dissec-
tion (R0 surgery). The postoperative period was uneventful but
characterized by a slow functional recovery, ineffective cough,
sputum retention and frequent episodes of atelectasis that
required bronchoscopies. On postoperative day 10, the patient
had fever (38.1C), cough, diarrhoea, hypotension and anaemia
without bleeding (haemoglobin 5.8 g/dl). Due to the presence in
the ward of patients infected with SARS-CoV-2, we performed
the pharyngeal swab test; the results of the test were positive.
The patient was then transferred to the SARS-CoV-2 isolation
ward for specific treatment. Unfortunately, the patient’s respira-
tory condition progressively deteriorated with the need for oxy-
gen and respiratory support. The CT scan showed bilateral
extended interstitial pneumonia. Because of further worsening of
his clinical condition, the patient was transferred to the COVID-
19 dedicated intensive care unit. After 24 h of non-invasive venti-
lation, mechanical ventilation was required. On postoperative
day 25, the patient exhibited acute renal failure; the patient
started continuous veno-venous haemodiafiltration (1000 U/h
prefilter heparin, 10 mg/h post-filter protamine sulphate).
Despite the treatment, his condition progressively worsened until
he died on postoperative day 32 of multiple organ failure.
Case 4
Case 4 was an 80-year-old male patient, admitted for elective
surgery because of a middle lobe NSCLC (cT1bN0M0). He was a
current smoker (10 pack/year), with a history of COPD and fre-
quent exacerbations, hypertension and peripheral arterial occlu-
sive disease. A CT scan showed a solitary nodule of the middle
lobe; a transbronchial guided biopsy revealed a primary squa-
mous cell carcinoma. The patient looked well, with no symp-
toms, so on day 1 of hospitalization, he had a robotic-assisted
middle lobectomy with hilar and mediastinal lymphadenecto-
mies. The postoperative period was characterized by a persistent
air leak that prolonged chest drain duration and hospitalization.
Broad-spectrum antibiotic (amoxicillin and clavulanate) therapy
was started on postoperative day 5. On postoperative day 16 the
patient suddenly had marked hypotension (blood pressure 85/
50 mmHg) and tachycardia; the results of a blood test showed
anaemia (haemoglobin 7.5 vs 11.70 g/dl the day before) and a
slight increase in the white blood cell count (14.30 vs
11.70 1012/l). Also on postoperative day 5, the patient had a
contrast enhanced CT scan that showed neither GGO in the
remaining lung nor active bleeding. The patient had no fever or
respiratory symptoms. However, due to the presence in the
ward of patients infected with SARS-CoV-2, we performed the
pharyngeal swab test on postoperative day 17; the results of the
test were positive. The same day he was moved to the SARS-
CoV-2 isolation unit for specific treatment. The patient was dis-
charged on postoperative day 30.
Case 5
Case 5 was a 79-year-old male patient, current smoker (60 pack/
year) and a history of alcohol abuse. He was admitted for evalu-
ation of a lung cancer of the right lung, cT1N0M0 after complete
staging. He had a medical history of psoriasis, bullous emphysema
and peripheral arterial occlusive disease of the lower limbs.
Because he had a persistent cough, we performed a chest CT scan.
The scan showed a solid nodule in the right lower lobe. The subse-
quent CT-guided biopsy resulted in the diagnosis of a primary
large-cell neuroendocrine carcinoma. His general condition was
good, without symptoms. On day 1 of hospitalization, the patient
had a thoracoscopic right lower lobectomy with hilar and medias-
tinal lymphadenectomies, without event. The postoperative period
was characterized by a slow functional recovery, with the frequent
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need of bronchoscopy for retained secretions with atelectasis and
prolonged psychiatric treatment for alcohol withdrawal. Due to
the presence of Klebsiella oxytoca on a bronchoalveolar aspiration
culture, antibiotic treatment with vancomycin and meropenem
was started on postoperative day 13. The patient never had a
fever, and laboratory findings were normal. His general condition
gradually improved. On postoperative day 17, a chest CT scan
showed consolidation of the right upper lobe, associated with
GGO in the same remaining lung. Because he was in the same
room as a patient found to be infected with SARS-CoV-2, on post-
operative day 20 he had the pharyngeal swab test, the results of
which were positive. The same day he was transferred to the
SARS-CoV-2 isolation ward for specific treatment. The patient’s
condition progressively improved, and he was discharged on
postoperative day 26. The final histological report revealed a
pT2aN0M0 small cell lung cancer.
DISCUSSION
On 11 March 2020, the World Health Organization declared the
SARS-CoV-2 epidemic a pandemic [7]. Since then, elective cancer
surgery has been disrupted around the world; surgeons have been
faced with questions and considerations unimaginable in the pre-
pandemic era. Should surgical treatment of lung cancer remain a
priority? Which patients with lung cancer can wait for surgery and
which ones would be placed at greater risk by a coronavirus infec-
tion and concomitant lung cancer treatment? Clearly, we do not
Figure 1: Postoperative chest computed tomography images: (A) case 1; (B) case 2; (C) case 3; (D) case 4; (E) case 5.
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have a definitive answer, but we have made some recommenda-
tions based on our case series of 5 patients surgically treated and
infected with SARS-CoV-2 during the perioperative period. In our
5 patients with lung cancer, the presence of SARS-CoV-2 was ‘acci-
dental’, and surgical treatment was performed when the superim-
posed infection was not recognized. Liang et al. [8] recently
suggested that patients with cancer are more likely to be infected
with the virus because of their immune depressed state induced
by the oncological treatment (chemotherapy or surgery) and by
the cancer itself. This study was performed on 18 patients with
cancer among a population of 2007 patients diagnosed with
SARS-CoV-2, which is a small number. The authors emphasized
that patients with cancer are at higher risk of developing severe
disease (39% vs 8%). Also, patients who have been operated on or
who have had anticancer chemotherapy in the month preceding
the appearance of the virus had a higher risk (75%) of developing
life-threatening disease than those who had not had surgery or
chemotherapy (43%). The 5 patients with lung cancer included in
our series showed a lower probability of severe events compared
with patients with other types of cancers (1, 20% vs 8, 62%).
Otherwise, Tian et al. [9] reported the results of the pathological
examinations of 2 patients who had lobectomies performed for a
primary adenocarcinoma and who retrospectively were found to
have had COVID-19 at the time of surgery; they reported a mor-
tality of 50% for those who had COVID-19.
The first consideration is that our patient outcomes were worse
than those reported by Liang et al.: we actually observed 40% mor-
tality in patients with severe COVID-19; the morbidity in 60% was
associated with a long hospital stay (mean 33.8 days). An early stage
lung cancer treated with a minimally invasive procedure is appar-
ently associated with a better outcome. An immediate consequence
of the presence of SARS-CoV-2-infected patients within the thor-
acic unit was that, since then, all patients scheduled for surgery,
even those who were asymptomatic, have had a nasopharyngeal
swab test 2 days before hospitalization. However, the clinical course
and the pathological status of these cases can also be discussed for
other reasons. All patients had primary lung cancer; thus, according
to national rules, the surgical procedure was considered a high pri-
ority, meaning that the treatment must be performed ‘within a
month from diagnosis’. Because lung cancer surgery is considered
as an ‘urgent’ surgery worldwide, 2 questions have become of fun-
damental importance for the thoracic surgeon: which lung cancer
procedures can be delayed and which lung cancer patients are
more at risk from in-hospital infection with SARS-CoV-2 during the
postoperative period. In light of the continuing lack of resources,
many institutions are negotiating a reduction in elective lung cancer
procedures. So, the question is, what kind of surgery should be
considered immediately ‘necessary’ and not to be delayed.
Which lung cancer surgical procedures cannot be
delayed?
The first answer may be surgical procedures for advanced stage
lung cancer, because a delay of few months in this setting could
mean progression towards inoperability. Another possible answer
is patients undergoing multimodality treatment, at the end of
their induction treatment, to be operated within 4–6 weeks after
the end of neoadjuvant therapy.
Recently, the Thoracic Surgery Outcomes Research Network
[10] provided a guide for triaging patients with thoracic malig-
nancies during the COVID-19 pandemic. They defined 3 phases
of hospital status based on the prevalence of patients with
COVID-19 within the hospital: the availability of hospital resour-
ces; the prevalence of infections; and the consequent resource
depletion. Phase I is defined by the presence of few COVID-19
patients and intact hospital resources. Phase I can be considered
to correspond to our scenario: The guideline in this setting is to
consider that the surgical procedure should be performed as
soon as feasible in the case of a solid or predominantly solid
(>50%) lung cancer, lung cancer >_2 cm, node-positive lung cancer
and post induction therapy cancer. Although our case series met
these indications, the results were not particularly satisfactory. In
patients with stage IIIA lung cancer, a delay >3 months between
the onset of neoadjuvant therapy and surgery has been associ-
ated with significantly reduced median survival [11, 12]. This situ-
ation describes the scenarios of our cases 2 and 3. Unfortunately,
in these patients, infection with SARS-CoV-2 resulted in severe
cases of COVID-19 that ended in death (not related to other in-
fectious causes or complications). Moreover, surgical procedures
for patients with advanced stages is more prone to postoperative
complications, and the reduced availability of resources in inten-
sive care units could jeopardize their management. On the other
hand, patients with early stage lung cancer treated by minimally
invasive surgery had a prolonged hospital stay (but outside inten-
sive care) with successful outcomes. Moreover, in patients with
stage I lung cancer, an interval between diagnosis and surgery
greater than only 8 weeks has been reported to be associated
with a significant reduction in the 5-year survival rate [13].
Which patients are more at risk in case of
in-hospital infection?
Phase II as defined by the Thoracic Surgery Outcomes Research
Network [10] is characterized by the presence of many COVID-19
patients with the consequent major limitation of logistical and
human resources. In this scenario, surgery should be restricted to
patients whose survival is likely to be compromised if the surgery is
delayed by a few days; all elective thoracic procedures should be
deferred (3 months). Based on our case series, patients with early
stage lung cancer treated with minimally invasive procedures had
longer and more complicated recovery times mainly due to the co-
existence of the symptoms and complications of COVID-19, but
they were able to overcome the disease without the need for inva-
sive ventilation. These results suggest that early stage lung cancer
could be treated during the SARS-CoV-2 epidemic with moderate
risk in patients with hospital-acquired infection. In contrast, patients
with advanced stages of lung cancer and complex surgical proce-
dures are prone to fatal complications from COVID-19, so they
should be treated only if a completely SARS-CoV-2-free hospital
pathway can be guaranteed or if the procedure cannot be post-
poned for urgent clinical reasons. In any case, the potential risks of
postponing or proceeding with treatment should be accurately bal-
anced on a case by case basis and discussed with the patient.
This case series has some obvious limitations due to the small
sample size and to the different baseline characteristics, including
comorbidities and preoperative pulmonary lung function.
Moreover, due to the retrospective nature of the analysis, the
date of exposure and the time of onset of the disease can only
be presumed. Because of the shortage of nasopharyngeal cor-
onavirus swab tests, its prescription at that time was allowed only
by the department of public health and by the infectious disease







603A. Gonfiotti et al. / European Journal of Cardio-Thoracic Surgery
situation limited the extension of the study to all the patients
operated on during the same period.
CONCLUSIONS
Based on our case series, surgery for lung cancer is a risk factor for
developing severe COVID-19, particularly in patients with advanced
stages of lung cancer. Therefore, in patients scheduled for lung can-
cer surgery during the SARS-CoV-2 outbreak, we suggest the follow-
ing steps: (i) perform a preoperative SARS-CoV-2 nasopharyngeal
swab test; if the test result is positive, consider postponing the surgi-
cal procedure; (ii) in endemic areas, consider intentional postpone-
ment of adjuvant chemotherapy or elective surgery for stable cancer
in an advanced stage; (iii) provide the strongest protection possible
for patients with lung cancer after their in-hospital admission; (iv)
consider hospital surveillance or treatment in both the intensive
care unit and the regular wards; and (v) have a multidisciplinary can-
cer board to guide the most appropriate therapeutic choice for
each patient and consider alternative treatments.
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